Loading...
Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
Trastuzumab deruxtecan (T-DXd) is a novel anti-human epidermal growth factor receptor 2 (HER2) antibody–drug conjugate composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor, DX-8951 derivative (an exatecan derivative). T-DXd showed potential anti-tumor activities in HER2-positi...
Na minha lista:
| Udgivet i: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7797586/ https://ncbi.nlm.nih.gov/pubmed/33473250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920986518 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|